National Quality Indicator – Prescribing Continuous Prophylaxis
Increase the proportion of severe hemophilia A patients over the age of two years for whom continuous prophylaxis was prescribed in the past year by age category.
| 2014 Baseline: | 2015 Result: | 2016 Most Recent Result: |
| 3-12 years: 72.8% 13-18 years: 77.6% 19-29 years: 64.6% 30-49 years: 45.4% 50-74 years: 33.21 |
3-12 years: 77.9% 13-18 years: 82.1% 19-29 years: 69.0% 30-49 years: 51.7% 50-74 years: 39.2% |
3-12 years: 81.93% 13-18 years: 88.33% 19-29 years: 76.99% 30-49 years: 59.94% 50-74 years: 47.43% |
| Total: 2,189 | Total: 2,533 | Total: 2,945 |
Calculation:
Numerator: Number of active patients with severe hemophilia A without an inhibitor who were prescribed continuous prophylaxis during the past calendar year by age category.
Denominator: Number of active patients with severe hemophilia A without an inhibitor by age category.
2015 Conclusion: The proportion of patients with severe hemophilia A without an inhibitor over the age of 2 years who were prescribed continuous prophylaxis during the past calendar year ranged from 39.16% for patients ages 50-74 and peaked at 82.14% for ages 13-18 years. Slight increases were seen across all ages between 3 and 74 years.
2016 Conclusion: The proportion of patients with severe hemophilia A without an inhibitor over the age of 2 years who were prescribed continuous prophylaxis during the past calendar year ranged from 47.43% for patients ages 50-74 and peaked at 88.33% for ages 13-18 years. Slight increases were seen across all ages between 3 and 74 years.